Loading...

Alector, Inc.

ALECNASDAQ
Healthcare
Biotechnology
$2.00
$-0.23(-10.31%)

Alector, Inc. (ALEC) Financial Performance & Income Statement Overview

Explore the financials of Alector, Inc. (ALEC), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
3.60%
3.60%
Operating Income Growth
4.44%
4.44%
Net Income Growth
8.70%
8.70%
Operating Cash Flow Growth
-24.84%
24.84%
Operating Margin
-165.80%
165.80%
Gross Margin
38.76%
38.76%
Net Profit Margin
-142.10%
142.10%
ROE
-112.06%
112.06%
ROIC
-49.44%
49.44%

Alector, Inc. (ALEC) Income Statement & Financial Overview

Analyze Alector, Inc.’s ALEC earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$3.67M$54.24M$15.34M$15.08M
Cost of Revenue$0.00$0.00$0.00$2.28M
Gross Profit$3.67M$52.16M$15.34M$12.80M
Gross Profit Ratio$1.00$0.96$1.00$0.85
R&D Expenses$33.64M$44.38M$48.00M$44.03M
SG&A Expenses$14.73M$15.03M$15.78M$14.38M
Operating Expenses$48.37M$61.49M$63.78M$58.41M
Total Costs & Expenses$48.37M$68.34M$63.78M$60.69M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$1.85M$2.08M$2.19M$2.28M
EBITDA-$42.85M-$5.17M-$46.24M-$44.20M
EBITDA Ratio-$11.66-$0.10-$3.01-$2.93
Operating Income-$44.70M-$7.25M-$48.43M-$45.61M
Operating Income Ratio-$12.17-$0.13-$3.16-$3.02
Other Income/Expenses (Net)$4.22M$5.22M$6.21M$7.003M
Income Before Tax-$40.47M-$2.03M-$42.22M-$38.60M
Income Before Tax Ratio-$11.02-$0.04-$2.75-$2.56
Income Tax Expense$0.00$48000.00$0.00$73000.00
Net Income-$40.47M-$2.07M-$42.22M-$38.68M
Net Income Ratio-$11.02-$0.04-$2.75-$2.56
EPS-$0.41-$0.02-$0.44-$0.40
Diluted EPS-$0.41-$0.02-$0.44-$0.40
Weighted Avg Shares Outstanding$99.40M$98.32M$96.67M$96.67M
Weighted Avg Shares Outstanding (Diluted)$99.40M$98.32M$96.67M$96.67M

Over the last four quarters, Alector, Inc. achieved steady financial progress, growing revenue from $15.08M in Q2 2024 to $3.67M in Q1 2025. Gross profit stayed firm with margins at 100% in Q1 2025 versus 85% in Q2 2024. Operating income totaled -$44.70M in Q1 2025, maintaining a -1217% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$42.85M. Net income dropped to -$40.47M, with EPS at -$0.41. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;